2022
Accelerated epigenetic aging in newborns with Down syndrome
Xu K, Li S, Muskens IS, Elliott N, Myint SS, Pandey P, Hansen HM, Morimoto LM, Kang AY, Ma X, Metayer C, Mueller BA, Roberts I, Walsh KM, Horvath S, Wiemels JL, de Smith A. Accelerated epigenetic aging in newborns with Down syndrome. Aging Cell 2022, 21: e13652. PMID: 35661546, PMCID: PMC9282838, DOI: 10.1111/acel.13652.Peer-Reviewed Original ResearchConceptsDown syndromeAge accelerationEpigenetic age accelerationGestational age accelerationEarly-onset Alzheimer's diseaseTransient abnormal myelopoiesisPotential confounding factorsEpigenetic agingPremature agingSomatic GATA1 mutationsDS patientsAbnormal myelopoiesisBlood cell proportionsNewbornsAlzheimer's diseaseConfounding factorsBrain tissueCell proportionGATA1 mutationsEndocrine systemBloodTargeted sequencingSomatic mutationsSyndromeDisease
2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndrome
2017
121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.Peer-Reviewed Original Research
2016
Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394. DOI: 10.1182/blood.v128.22.394.394.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaMyelodysplastic syndromeSurvival benefitHigh-risk myelodysplastic syndromeDemonstrated survival benefitRetrospective cohort studyRisk myelodysplastic syndromesUse of HMAsAgent azacitidineLack of evidenceCohort studyClinical entityMyelomonocytic leukemiaBiologic evidenceOlder adultsAzacitidineUnited StatesHMAsEnd resultPatientsSyndromeLeukemiaDecitabineEpidemiologyFactors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database.
Scott B, Kiselev P, Fliss A, Huang M, Steensma D, Ma X, Swern A, Sugrue M. Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database. Journal Of Clinical Oncology 2016, 34: e18548-e18548. DOI: 10.1200/jco.2016.34.15_suppl.e18548.Peer-Reviewed Original Research
2015
Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS)
Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia 2015, 15: s44-s45. DOI: 10.1016/j.clml.2015.07.094.Peer-Reviewed Original Research
2014
Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry.
Steensma D, Abedi M, Attar E, Bejar R, Cogle C, Garcia-Manero G, Grinblatt D, Ma X, Maciejewski J, Pollyea D, Roboz G, Savona M, Scott B, Sekeres M, Thompson M, Zernovak O, Sugrue M, Swern A, Nifenecker M, Erba H. Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. Journal Of Clinical Oncology 2014, 32: tps7126-tps7126. DOI: 10.1200/jco.2014.32.15_suppl.tps7126.Peer-Reviewed Original Research
2012
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research 2012, 36: 1370-1375. PMID: 22917770, PMCID: PMC3458648, DOI: 10.1016/j.leukres.2012.07.020.Peer-Reviewed Original ResearchConceptsCost of careMyelodysplastic syndromeMDS patientsMedicare expendituresComparative cost-effectiveness studyCohort of patientsTwo-year survivalNon-cancer controlsCost-effectiveness studiesElderly patientsPrevalent cancerEconomic burdenPatientsMajor subtypesSurvivalCareSyndromeUnited StatesHMAsSurvival probabilityEarly periodCohortAgentsCancerSubtypesEpidemiology of Myelodysplastic Syndromes
Ma X. Epidemiology of Myelodysplastic Syndromes. The American Journal Of Medicine 2012, 125: s2-s5. PMID: 22735748, PMCID: PMC3394456, DOI: 10.1016/j.amjmed.2012.04.014.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeIncidence of MDSBetter risk-stratify patientsClonal hematopoietic stem cell malignanciesHematopoietic stem cell malignanciesRisk-stratify patientsStem cell malignanciesMore effective treatmentsMDS prognosisDifferent comorbiditiesPrognostic factorsSignificant morbidityEtiologic factorsDisease burdenPoor survivalEffective treatmentCell malignanciesHigh mortalityNew casesHeterogeneous groupComorbiditiesSyndromeDiseaseRecent studiesPotential interactions
2010
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Maggiore RJ, Halene S, Soulos PR, Raza A, Galili N, Ma X. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leukemia Research 2010, 35: 904-908. PMID: 21067809, PMCID: PMC3114277, DOI: 10.1016/j.leukres.2010.10.007.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromePatient characteristicsRefractory anemiaMultivariate logistic regression modelMultiple patient characteristicsPopulation-based studyUse of HMAsLogistic regression modelsElderly patientsExcess blastsMultilineage dysplasiaRefractory cytopeniaMDS patientsPatientsComorbiditiesAnemiaSyndromeHigher chanceRegression modelsHMAsAgentsIntroduction periodCytopeniasDysplasiaCancer
2007
Clustering in the incidence of myelodysplastic syndromes
Ma X, Selvin S, Raza A, Foti K, Mayne ST. Clustering in the incidence of myelodysplastic syndromes. Leukemia Research 2007, 31: 1683-1686. PMID: 17507092, DOI: 10.1016/j.leukres.2007.03.032.Peer-Reviewed Original ResearchConceptsIncidence of MDSMyelodysplastic syndromePopulation-based cancer registry dataEtiology of MDSPopulation-based dataCancer registry dataGroup of malignanciesPoor prognosisObscure etiologyPotential clusteringRegistry dataHigh incidenceEtiologic hypothesesLarger sample sizeIncidenceSyndromeP-valueEtiologyFuture studiesState of ConnecticutCensus tractsSample sizeIntriguing findingPrognosisMalignancy